Close Menu

Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Large-scale population sequencing projects and consumer genomics markets are picking up and oncology continues to be a strong market for Illumina.

Strength in sequencing and array consumables as well as the firm's services drove second quarter revenues to $830 million, easily surpassing analyst estimates.

OrigiMed is a Shanghai, China-based company focusing on the development of new oncology assays.

Illumina is working on further reducing turnaround time of the analysis and on detecting structural variants and repeat expansions.

Illumina has extended a supply agreement with Foundation until 2023 and developed an automated metagenomics workflow with PerkinElmer.

Illumina said the acquisition will help enable a standardized process for sequencing and analysis and speed up the time it take to get a result.

The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.

CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.

Luna DNA, which offers a cryptocurrency to reward people for sharing biological and medical data with researchers, has raised $4 million to date.

The effort aims to sequence at least 150 animals, plants, and microbes selected for their potential benefits to Canada in the next three years.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.